News and Comments

INCYTE: SHOWS ITS PATH TOWARDS GROWTH

  Wednesday, February 12, 2014

 More...

HALOZYME: FINANCING PEGPH20 IS WORTH RAISING MONEY

  Wednesday, February 05, 2014

Halozyme Therapeutics (HALO) stock has been a loser yesterday while other biotech firms have rebounded after dipping during the few days’ of an angry market. The reason for the stock decline was the announcement of pricing of Halozyme’s previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share.  More...


Recent Postings


Archive


Tags

HALOZYME (HALO) Cytokinetics (CYTK) Array Pharmaceuticals (ARRY) Endometrial Cancer Alnylam (ALNY) Sarepta (SRPT) Micromet (MITI) Agenus (AGEN BIOMARIN (BMRN) SUNESIS PHARMACEUTICALS (SNSS) Zerenex Agenus (AGEN) ImmunoGen (IMGN) Jazz Pharmaceuticals (JAZZ) Illumina (ILMN) KITE (KITE) Ariad (ARIA) Telaprevir Biogen Idec (BIIB) Auspex (ASPX) Onyx (ONXX) NEKTAR (NKTR)) Sanofi-Aventis (SAN) Xoma (XOMA) Aimmune Therapeutics (AIMT) ARCA (ABIO) Sangamo (SGMO) ZALTRAP™ Intercept (ICPT) Biocryst (BCRX) Intrexon (XON) Rapamune Multiple Myeloma Theravance (THRX) galapagos (GLPG) VANDA (VNDA) SYNTA (SNTA) Ridaforolimus Sanofi (SNY) Dynavax (DVAX) Bristol-Myers Squibb (BMY) Idenix (IDIX) Sequenom (SQNM) Herceptin Galena (GALE) SERES THERAPEUTICS (MCRB) Valeant Pharmaceuticals International (VRX) Trastuzumab-DM1 Intermune (ITMN) Ziofpharm (ZIOP) TOKAI (TKAOI) JUNO (JUNO) KERYX (KERX) Incyte (INCY) Dendreon (DNDN) Pluristem (PSTI) Velcade (bortezomib) Roche (RHHBY) Roche (ROCHE) Vertex (VRTX) Human Genome Sciences (HGSI) Mirati Therapeutics (MRTX) Anadys (ANDS) Regeneron (REGN) Genentech Inovio (INO) ABBVIE (ABBV) Prosensa (RNA) Abbott Laboratories (ABT) ISIS (ISIS) Elan (ELN) Seattle Genetics (SGEN) Anacor (ANAC) NANTKWEST (NK) GlaxoSmithKline (GSK) GUARDIAN HEALTH Gilead (GILD) IDERA (IDRA) C4 Therapeutics OSI (OSIP) Tysabri ADVENTRIX (ANX) Exelixis (EXEL) Amgen (AMGN) Revlimid (lenolidamide) Sanofi (SNA) CompuGen (CGEN) AERIE PHARMACEUTICALS Merck (MRK) Benlysta (belimumab) Prolor Biotech (PBTH)